Assembly Biosciences, Inc.

As of March 28, 2024, Assembly Biosciences, Inc. is considered a risky investment due to its high Price to Book Value of 4.57, negative EV to EBIT and EV to EBITDA ratios, and a negative P/E ratio of -9.31, despite a year-to-date stock return of 41.13% that outperformed the S&P 500, while its long-term performance has significantly underperformed with an 89.36% decline over the past five years.

As of March 28, 2024, Assembly Biosciences, Inc. is rated as risky and overvalued due to poor financial ratios, including a Price to Book Value of 4.57 and a ROE of -147.12%, despite a year-to-date stock return of 8.37% outperforming the S&P 500's 2.44%.

As of May 27, 2025, the technical trend is mildly bullish, supported by bullish weekly MACD and Bollinger Bands, despite short-term weakness indicated by daily moving averages.

As of March 2022, the management team of Assembly Biosciences, Inc. includes Mr. William Ringo as Non-Executive Independent Chairman and Dr. John McHutchison as President and CEO, along with independent directors Mr. Anthony Altig, Ms. Gina Consylman, Dr. Richard DiMarchi, and Mr. Myron Holubiak.

Assembly Biosciences, Inc. is a biotechnology company focused on developing oral therapeutics for hepatitis B and synthetic live therapeutics for microbiome health. It has a market cap of $130.45 million, with recent net sales of $9 million and a net loss of $9 million.

As of Jun 18, Assembly Biosciences, Inc. has a market capitalization of 130.45 million and reported net sales of 32.15 million with a net profit of -39.92 million over the latest four quarters. The company's balance sheet shows shareholder's funds of 33.36 million and total assets of 119.97 million.